Search

Seasonal influenza has a significant impact on global public health each year, especially in older adults 65 years of age and above. This paper presents the evolution of high-dose influenza vaccine and the quantity as well as quality of evidence on this vaccine. Its introduces other peer-reviewed manuscripts included in this supplement covering the benefits high-dose influenza vaccine over ten consecutive influenza seasons. The development of the high-dose influenza vaccine represents an important step in the evolution of influenza vaccines, offering an advancement in prevention of influenza and a step in encouraging healthy aging in older adults. A video summary of the article can be accessed via the Supplementary data link at the end of this article., Competing Interests: Declaration of Competing Interest MD, LJC, BS, CR, AC, MM, DPG, RH, and SIS are employees of Sanofi Pasteur., (Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.)